{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:08:50Z","timestamp":1773515330224,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470368"],"award-info":[{"award-number":["81470368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"scientific research fund for the treatment of chronic anaemia in China","award":["LIM-SS-16001"],"award-info":[{"award-number":["LIM-SS-16001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00277-017-3157-9","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T02:26:30Z","timestamp":1509416790000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma"],"prefix":"10.1007","volume":"97","author":[{"given":"Wei Ping","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Feng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling Yan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi Tao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Juan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Gan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Qin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"3157_CR1","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Sch\u00fcnemann HJ, American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, Latin American Thoracic Association (2015) An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192:e3\u2013e19. \nhttps:\/\/doi.org\/10.1164\/rccm.201506-1063ST","journal-title":"Am J Respir Crit Care Med"},{"key":"3157_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1164\/rccm.201607-1484OC.","volume":"195","author":"S Singh","year":"2016","unstructured":"Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, Singh N, Ho L, Samaria JK, Bhattacharya P, Gupta R, Chaudhari S, Singh T, Moond V, Pipavath S, Ahuja J, Chetambath R, Ghoshal AG, Jain NK, Devi HJ, Kant S, Koul P, Dhar R, Sarnaker R, Sharma SK, Roy DJ, Sarmah KR, Jankharia B, Schmidt R, Katiyar SK, Jindal A, Mangal DK, Singh V, Raghu G (2016) Interstitial lung disease (ILD) in India: results of a prospective registry. Am J Respir Crit Care Med 195:801\u20138013. \nhttps:\/\/doi.org\/10.1164\/rccm.201607-1484OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"3157_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","volume":"87","author":"D Ennishi","year":"2008","unstructured":"Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Ikeda K, Tanimoto M, Hatake K (2008) Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 87:393\u2013397. \nhttps:\/\/doi.org\/10.1007\/s12185-008-0066-7","journal-title":"Int J Hematol"},{"key":"3157_CR4","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","volume":"23","author":"WG Martin","year":"2005","unstructured":"Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma. J Clin Oncol 23:7614\u20137620. \nhttps:\/\/doi.org\/10.1200\/JCO.2005.02.7243","journal-title":"J Clin Oncol"},{"key":"3157_CR5","doi-asserted-by":"publisher","first-page":"185362","DOI":"10.1155\/2013\/185362","volume":"2013","author":"WL Chen","year":"2013","unstructured":"Chen WL, Tsao YT, Chang TH, Chao TY, Kao WY, Chen YC, Ho CL (2013) Impact of interstitial pneumonia on the survival and risk factors analysis of patients with hematological malignancy. Biomed Res Int 2013:185362. \nhttps:\/\/doi.org\/10.1155\/2013\/185362","journal-title":"Biomed Res Int"},{"issue":"3","key":"3157_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1148\/radiol.2462070712","volume":"246","author":"DM Hansell","year":"2008","unstructured":"Hansell DM, Bankier AA, MacMahon H, McLoud TC, M\u00fcller NL, Remy J (2008) Fleischner Society: glossary of terms for thoracic imaging. Radiology 246(3):697\u2013722. \nhttps:\/\/doi.org\/10.1148\/radiol.2462070712","journal-title":"Radiology"},{"key":"3157_CR7","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00277-011-1268-2","volume":"90","author":"YC Huang","year":"2011","unstructured":"Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, Hsiao LT, Chao TC, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, YB Y, Tzeng CH (2011) Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 90:1145\u20131151. \nhttps:\/\/doi.org\/10.1007\/s00277-011-1268-2","journal-title":"Ann Hematol"},{"key":"3157_CR8","unstructured":"National Institutes of Health and National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. U.S. Department of Health and Human Services; National Institutes of Health and National Cancer Institute; 2010. \nhttp:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf\n\n."},{"key":"3157_CR9","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3109\/10428194.2014.963075","volume":"56","author":"G Salmasi","year":"2015","unstructured":"Salmasi G, Li M, Sivabalasundaram V, Panzarella T, Tsang R, Kukreti V, Crump M, Kuruvilla J (2015) Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma 56:1659\u20131664. \nhttps:\/\/doi.org\/10.3109\/10428194.2014.963075","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3157_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, Saijo Y, Sakai F, Sugiyama Y, Tatsumi K, Dohi M, Tokuda H, Hashimoto S, Hattori N, Hanaoka M, Fukuda Y, Japanese Respiratory Society Committee for formulation of Consensus statement for the diagnosis and treatment of drug-induced lung injuries (2013) Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51(4):260\u2013277. \nhttps:\/\/doi.org\/10.1016\/j.resinv.2013.09.001","journal-title":"Respir Investig"},{"key":"3157_CR11","doi-asserted-by":"publisher","unstructured":"Azadeh N, Limper AH, Carmona EM, Ryu JH (2017) The role of infection in interstitial lung diseases\u2014a review. Chest. \nhttps:\/\/doi.org\/10.1016\/j.chest.2017.03.033","DOI":"10.1016\/j.chest.2017.03.033"},{"key":"3157_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4143\/crt.2014.034.","volume":"47","author":"S Park","year":"2015","unstructured":"Park S, Kang CI, Chung DR, Peck KR, Kim WS, Kim SJ (2015) Clinical significance of non-neutropenic fever in the management of diffuse large B-cell lymphoma patients treated with rituximab-CHOP: comparison with febrile neutropenia and risk factor analysis. Cancer Res Treat 47:448\u2013457. \nhttps:\/\/doi.org\/10.4143\/crt.2014.034.","journal-title":"Cancer Res Treat"},{"key":"3157_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360. \nhttps:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"3157_CR14","doi-asserted-by":"publisher","unstructured":"Postow MA (2015, 2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book:76\u201383. \n10.14694\/EdBook_AM.2015.35.76","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"issue":"supple4","key":"3157_CR15","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals Oncol 28(supple4):iv119\u2013iv142. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Annals Oncol"},{"key":"3157_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2307\/3578635","volume":"136","author":"HE Ward","year":"1993","unstructured":"Ward HE, Kemsley L, Davies L, Holecek M, Berend N (1993) The effect of steroids on radiation-induced lung disease in the rat. Radiat Res 136:22\u201328. \nhttps:\/\/doi.org\/10.2307\/3578635","journal-title":"Radiat Res"},{"key":"3157_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/resp.12807","volume":"21","author":"M Hanada","year":"2016","unstructured":"Hanada M, Sakamoto N, Ishimatsu Y, Kakugawa T, Obase Y, Kozu R, Senjyu H, Izumikawa K, Mukae H, Kohno S (2016) Effect of long-term treatment with corticosteroids on skeletal muscle strength, functional exercise capacity and health status in patients with interstitial lung disease. Respirology 21:1088\u20131093. \nhttps:\/\/doi.org\/10.1111\/resp.12807","journal-title":"Respirology"},{"key":"3157_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1060028014566446","volume":"49","author":"T Sakurada","year":"2015","unstructured":"Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K (2015) Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 49:398\u2013404. \nhttps:\/\/doi.org\/10.1177\/1060028014566446","journal-title":"Ann Pharmacother"},{"key":"3157_CR19","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4187\/respcare.02560.","volume":"59","author":"R Gupta","year":"2014","unstructured":"Gupta R, Ettinger NA (2014) Beyond conventional therapy: role of pulse steroids in bleomycin induced lung injury. Respir Care 59:e9\u2013e12. \nhttps:\/\/doi.org\/10.4187\/respcare.02560.","journal-title":"Respir Care"},{"key":"3157_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3904\/kjim.2010.25.1.86","volume":"25","author":"KH Lim","year":"2010","unstructured":"Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS (2010) Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 25:86\u201392. \nhttps:\/\/doi.org\/10.3904\/kjim.2010.25.1.86","journal-title":"Korean J Intern Med"},{"key":"3157_CR21","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jjco\/hyu074","volume":"44","author":"M Tachihara","year":"2014","unstructured":"Tachihara M, Kobayashi K, Ishikawa Y, Hori S, Tamura D, Otera H, Funada Y, Nishimura Y (2014) Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease. Jpn J Clin Oncol 44:762\u2013764. \nhttps:\/\/doi.org\/10.1093\/jjco\/hyu074","journal-title":"Jpn J Clin Oncol"},{"key":"3157_CR22","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1080\/10428190802270886","volume":"49","author":"X Liu","year":"2008","unstructured":"Liu X, Hong XN, YJ G, Wang BY, Luo ZG, Cao J (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 49:1778\u20131783. \nhttps:\/\/doi.org\/10.1080\/10428190802270886","journal-title":"Leuk Lymphoma"},{"key":"3157_CR23","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3109\/10428190903258780","volume":"50","author":"H Katsuya","year":"2009","unstructured":"Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T, Takamatsu Y, Tamura K (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 50:1818\u20131823. \nhttps:\/\/doi.org\/10.3109\/10428190903258780","journal-title":"Leuk Lymphoma"},{"key":"3157_CR24","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/bjc.1997.614","volume":"76","author":"N Niitsu","year":"1997","unstructured":"Niitsu N, Iki S, Muroi K, Motomura S, Murakami M, Takeyama H, Ohsaka A, Urabe A (1997) Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96. Br J Cancer 76:1661\u20131666. \nhttps:\/\/doi.org\/10.1038\/bjc.1997.614","journal-title":"Br J Cancer"},{"issue":"4","key":"3157_CR25","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1183\/13993003.01670-2015","volume":"47","author":"E Haustraete","year":"2016","unstructured":"Haustraete E, Obert J, Diab S, Abbes S, Zini JM, Valade S, Lerolle N, Albin N, Arnulf B, Bouaziz JD, Hussenet C, Tazi A, Bergeron A (2016) Idelalisib-related pneumonitis. Eur Respir J 47(4):1280\u20131283. \nhttps:\/\/doi.org\/10.1183\/13993003.01670-2015","journal-title":"Eur Respir J"},{"issue":"8","key":"3157_CR26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2015-12-686873","volume":"127","author":"AR Mato","year":"2016","unstructured":"Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, Ganetsky A, Nasta S, Porter DL, Svoboda J, Nabhan C, Schuster SJ (2016) Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood 127(8):1064\u20131067. \nhttps:\/\/doi.org\/10.1182\/blood-2015-12-686873","journal-title":"Blood"},{"issue":"13","key":"3157_CR27","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","volume":"14","author":"A Younes","year":"2013","unstructured":"Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348\u20131356. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(13)70501-1","journal-title":"Lancet Oncol"},{"issue":"24","key":"3157_CR28","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","volume":"22","author":"M Nishino","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS (2016) PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22(24):6051\u20136060. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1320","journal-title":"Clin Cancer Res"},{"key":"3157_CR29","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/resp.12787","volume":"21","author":"YK Lee","year":"2016","unstructured":"Lee YK, Huh R, Kim J, Ahn K, Sung KW, Cho J (2016) Late-onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients. Respirology 21:1068\u20131074. \nhttps:\/\/doi.org\/10.1111\/resp.12787","journal-title":"Respirology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3157-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3157-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3157-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T17:01:34Z","timestamp":1514826094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3157-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3157"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3157-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,31]]}}}